Logan Coy Related postsA Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Advanced CancerSeptember 11, 2026A Phase 1/2a, Open-Label Study of SA53-OS, an MDM2 Inhibitor, in Locally Advanced or Metastatic p53 Wild-Type Solid TumorsSeptember 11, 2026An Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR MutationsSeptember 11, 2026 Previous postA Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Advanced CancerNext postA Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1311 in Advanced/Metastatic Solid Tumors
